KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Takeda Pharmaceutical (TAK) Interest Expenses (2017 - 2025)

Historic Interest Expenses for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to -$803.2 million.

  • Takeda Pharmaceutical's Interest Expenses fell 15760.68% to -$803.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$4.1 billion, marking a year-over-year decrease of 54294.09%. This contributed to the annual value of $1.4 billion for FY2025, which is 953.92% down from last year.
  • Takeda Pharmaceutical's Interest Expenses amounted to -$803.2 million in Q4 2025, which was down 15760.68% from -$2.1 billion recorded in Q3 2025.
  • Over the past 5 years, Takeda Pharmaceutical's Interest Expenses peaked at $4.0 billion during Q1 2021, and registered a low of -$2.1 billion during Q3 2025.
  • Moreover, its 5-year median value for Interest Expenses was -$421.6 million (2022), whereas its average is -$49.3 million.
  • Per our database at Business Quant, Takeda Pharmaceutical's Interest Expenses surged by 73931.77% in 2024 and then plummeted by 15760.68% in 2025.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Interest Expenses stood at -$410.9 million in 2021, then tumbled by 37.38% to -$564.5 million in 2022, then soared by 50.62% to -$278.7 million in 2023, then fell by 11.86% to -$311.8 million in 2024, then tumbled by 157.61% to -$803.2 million in 2025.
  • Its Interest Expenses was -$803.2 million in Q4 2025, compared to -$2.1 billion in Q3 2025 and -$556.3 million in Q2 2025.